Advertisement

Corrigendum to ‘The outcome of two SMA cases treated with nusinersen at seven hours and at three days of life: the earliest ever’ [Neuromuscular Disorders 32 (2022) 575–577]

Open AccessPublished:September 21, 2022DOI:https://doi.org/10.1016/j.nmd.2022.09.004
      The authors regret the birthweight and developmental milestones of case 2 vary slightly from the original publication. These discrepancies do not affect the validity of the article. The authors would like to apologise for any inconvenience caused.
      The child was delivered by caesarean at 38 weeks and 4 days, not 39 weeks.
      Her birth weight was 3.11kg, not 3.16
      On day 1849 she was 5 years old, not 4 1/2.
      Walk test 321.5, not 329.
      Table 1. Case 2 corrected figures (age in months):
      Sitting without support: 5.7 (not 6)
      Hands & knees crawling: 9.5 (not 8)
      Standing with assistance: 8.6 (not 11)
      Walking with assistance: 9.1 (not 13)
      Standing alone: 10.3 (not 13)
      Walking alone: 12.3 (not 14)
      CMAP (from right tibialis anterior): 1.30 mV at 61 months (not 54)

      Linked Article

      • The outcome of two SMA cases treated with nusinersen at seven hours and at three days of life: the earliest ever
        Neuromuscular DisordersVol. 32Issue 7
        • Preview
          Early diagnosis is essential in spinal muscular atrophy. By the end of 2016, two alternative therapies had been developed and approved sequentially over a three- to four-year period: nusinersen, an intrathecally administered antisense oligonucleotide molecule to promote the production of a full-length transcript from the homologous gene SMN2 [1], and an AAV9 virus-based SMN1 gene replacement therapy [2]. However, treating SMA children by such means was never free of concerns, leading to raised eyebrows soon after wide clinical application.
        • Full-Text
        • PDF